IN2014CN04498A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04498A IN2014CN04498A IN4498CHN2014A IN2014CN04498A IN 2014CN04498 A IN2014CN04498 A IN 2014CN04498A IN 4498CHN2014 A IN4498CHN2014 A IN 4498CHN2014A IN 2014CN04498 A IN2014CN04498 A IN 2014CN04498A
- Authority
- IN
- India
- Prior art keywords
- domain
- sequence
- terminus
- amino acid
- protein
- Prior art date
Links
- 239000012634 fragment Substances 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000001243 protein synthesis Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL397167A PL397167A1 (pl) | 2011-11-28 | 2011-11-28 | Przeciwnowotworowe bialko fuzyjne |
| PCT/IB2012/056806 WO2013080147A2 (en) | 2011-11-28 | 2012-11-28 | Anticancer fusion protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04498A true IN2014CN04498A (enrdf_load_html_response) | 2015-09-11 |
Family
ID=47561689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4498CHN2014 IN2014CN04498A (enrdf_load_html_response) | 2011-11-28 | 2012-11-28 |
Country Status (18)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20200553T1 (hr) | 2013-03-12 | 2020-07-10 | Molecular Templates, Inc. | Citotoksični proteini koji sadrže vezne regije koje ciljaju na stanice i regije podjedinice a shiga toksina za selektivno ubijanje specifičnih tipova stanica |
| WO2014141094A1 (en) | 2013-03-14 | 2014-09-18 | Adamed Sp. Z O.O. | Anticancer conjugate |
| ES2749862T3 (es) | 2014-01-27 | 2020-03-24 | Molecular Templates Inc | Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos |
| US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
| EP3116905B1 (en) * | 2014-03-11 | 2019-01-30 | Molecular Templates, Inc. | Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs |
| ES2919749T3 (es) * | 2014-06-11 | 2022-07-28 | Molecular Templates Inc | Moléculas dirigidas a células citotóxicas resistentes a la escisión por proteasa |
| EP3795594A1 (en) | 2015-02-05 | 2021-03-24 | Molecular Templates, Inc. | Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof |
| WO2016127346A1 (zh) * | 2015-02-11 | 2016-08-18 | 四川大学华西医院 | 一种肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途 |
| EP3303373B1 (en) * | 2015-05-30 | 2020-04-08 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
| CN106380521B (zh) * | 2015-07-02 | 2020-12-29 | 博际生物医药科技(杭州)有限公司 | 用于肿瘤靶向治疗的白细胞介素-15融合蛋白 |
| KR101732126B1 (ko) | 2015-11-05 | 2017-05-02 | 한국생명공학연구원 | 췌장암 치료용 융합 단백질 및 이의 용도 |
| PL233352B1 (pl) * | 2016-09-15 | 2019-10-31 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe białko fuzyjne |
| EP3551645A1 (en) | 2016-12-07 | 2019-10-16 | Molecular Templates, Inc. | Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation |
| CN106632680A (zh) * | 2016-12-27 | 2017-05-10 | 上海交通大学 | 植物体系表达人源化抗agr2单克隆抗体18a4的质粒构建 |
| EP3573648B1 (en) | 2017-01-25 | 2023-11-22 | Molecular Templates, Inc. | Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes |
| WO2019173478A2 (en) * | 2018-03-06 | 2019-09-12 | The Johns Hopkins University | Methods of treating or preventing cancer with an agent that depletes tregs and a checkpoint inhibitor |
| CA3097178A1 (en) | 2018-04-17 | 2019-10-24 | Molecular Templates, Inc. | Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds |
| EP3984546A4 (en) * | 2019-05-15 | 2023-09-27 | Universidad de Granada | GENE THERAPY WITH THE HOKD AND LDRB GENES FOR CANCER TREATMENTS |
| CN113354738B (zh) * | 2020-03-05 | 2022-09-09 | 绍兴德方华生物技术有限公司 | 融合毒素VEGF165b/mGEL及其编码基因与应用 |
| CA3187245A1 (en) * | 2020-08-17 | 2022-02-24 | Sebastien Mercx | Recombinant immunotoxin comprising a ribotoxin or rnase |
| CN114681599B (zh) * | 2020-12-31 | 2024-07-02 | 中国科学院上海药物研究所 | 一种阳离子脂质体疫苗及其制备方法和用途 |
| CN117384859B (zh) * | 2023-12-13 | 2024-03-22 | 北京翊博生物集团有限公司 | 一种树突状细胞来源的外泌体的制备方法及应用 |
| CN118792375B (zh) * | 2024-06-25 | 2025-09-23 | 华南农业大学 | 一种具有补肾壮阳功效的瓜蒌多肽及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1666591E (pt) | 1995-06-29 | 2011-06-01 | Immunex Corp | Citoquina que induz apoptose |
| WO2001060393A1 (en) | 2000-02-16 | 2001-08-23 | Bechtel Bwxt Idaho, Llc | Selective destruction of cells infected with human immunodeficiency virus |
| ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| CN1257187C (zh) * | 2003-10-22 | 2006-05-24 | 上海恰尔生物技术有限公司 | 钙网蛋白－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途 |
| JP4688678B2 (ja) | 2003-11-03 | 2011-05-25 | 北京沙東生物技術有限公司 | 抗癌作用を有する組換えタンパク質、それをコードする遺伝子、及びそれらの使用 |
| US7252993B2 (en) | 2004-03-12 | 2007-08-07 | Battelle Energy Alliance, Llc | Plasmids encoding therapeutic agents |
| EP3006456B1 (en) | 2005-07-29 | 2018-09-19 | The Government of the United States of America, as represented by the Secretary of Health and Human Services | Mutated pseudomonas exotoxins with reduced antigenicity |
| CA2619842A1 (en) | 2005-08-16 | 2007-02-22 | Genentech, Inc. | Apoptosis sensitivity to ap02l/trail by testing for 'galnac-t14 expression in cells/tissues |
| CA2668017A1 (en) | 2006-10-30 | 2008-05-08 | Viventia Biotech Inc. | Improved conjugates |
| BRPI0720647A2 (pt) | 2006-12-29 | 2014-01-14 | Osprey Pharmaceuticals Usa Inc | Processos de seleção e produção de toxinas modificadas, conjugados contendo toxinas modificadas e usos dos mesmos |
| US20090131317A1 (en) | 2007-06-22 | 2009-05-21 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
| GB0723059D0 (en) | 2007-11-23 | 2008-01-02 | Nat Univ Ireland | Improved cytokine design |
| GB0724532D0 (en) | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
| ES2633453T3 (es) * | 2008-01-24 | 2017-09-21 | Esperance Pharmaceuticals | Constructos de fusión de dominios líticos y métodos de preparación y utilización de los mismos |
| WO2009140469A2 (en) | 2008-05-14 | 2009-11-19 | Genentech, Inc. | Methods of using apo2l/trail to treat cancer |
| EP2297198B1 (en) * | 2008-06-30 | 2014-12-17 | University Of Pennsylvania | Fn14/trail fusion proteins |
-
2011
- 2011-11-28 PL PL397167A patent/PL397167A1/pl unknown
-
2012
- 2012-11-28 MX MX2014006369A patent/MX2014006369A/es unknown
- 2012-11-28 HK HK15102260.2A patent/HK1201727A1/xx unknown
- 2012-11-28 EP EP12816127.0A patent/EP2785362A2/en not_active Withdrawn
- 2012-11-28 KR KR1020147018001A patent/KR20140097529A/ko not_active Withdrawn
- 2012-11-28 US US14/361,279 patent/US20150044162A1/en not_active Abandoned
- 2012-11-28 CA CA2856480A patent/CA2856480A1/en not_active Abandoned
- 2012-11-28 CN CN201280058346.6A patent/CN103974711A/zh active Pending
- 2012-11-28 IN IN4498CHN2014 patent/IN2014CN04498A/en unknown
- 2012-11-28 SG SG11201402312WA patent/SG11201402312WA/en unknown
- 2012-11-28 WO PCT/IB2012/056806 patent/WO2013080147A2/en active Application Filing
- 2012-11-28 BR BR112014012808A patent/BR112014012808A2/pt not_active IP Right Cessation
- 2012-11-28 JP JP2014544020A patent/JP2015500228A/ja active Pending
- 2012-11-28 EA EA201491049A patent/EA201491049A1/ru unknown
- 2012-11-28 AU AU2012345494A patent/AU2012345494A1/en not_active Abandoned
-
2014
- 2014-05-14 PH PH12014501083A patent/PH12014501083A1/en unknown
- 2014-05-21 IL IL232743A patent/IL232743A0/en unknown
- 2014-06-25 ZA ZA2014/04667A patent/ZA201404667B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12014501083A1 (en) | 2014-08-04 |
| CA2856480A1 (en) | 2013-06-06 |
| HK1201727A1 (en) | 2015-09-11 |
| CN103974711A (zh) | 2014-08-06 |
| MX2014006369A (es) | 2014-07-09 |
| EA201491049A1 (ru) | 2014-10-30 |
| BR112014012808A2 (pt) | 2019-09-24 |
| SG11201402312WA (en) | 2014-06-27 |
| EP2785362A2 (en) | 2014-10-08 |
| PL397167A1 (pl) | 2013-06-10 |
| US20150044162A1 (en) | 2015-02-12 |
| IL232743A0 (en) | 2014-07-31 |
| WO2013080147A2 (en) | 2013-06-06 |
| ZA201404667B (en) | 2015-09-30 |
| JP2015500228A (ja) | 2015-01-05 |
| KR20140097529A (ko) | 2014-08-06 |
| AU2012345494A1 (en) | 2014-07-10 |
| WO2013080147A3 (en) | 2014-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN04498A (enrdf_load_html_response) | ||
| PL393578A1 (pl) | Przeciwnowotworowe białko fuzyjne | |
| PH12013500714A1 (en) | Anticancer fusion protein | |
| NZ712148A (en) | Wt1 antigen peptide conjugate vaccine | |
| IN2014KN01715A (enrdf_load_html_response) | ||
| MX2014008028A (es) | Proteina de fusion anticancerigena. | |
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012008998A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| NZ629843A (en) | Identification of channelrhodopsin-2 (chop2) mutations and methods of use | |
| MX342291B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| NZ630536A (en) | Therapeutic agent or prophylactic agent for dementia | |
| BR112017009790A2 (pt) | anticorpos direcionados ao anti-ang2 e métodos de uso | |
| PH12013501970A1 (en) | Anticancer fusion protein | |
| WO2010011952A3 (en) | Flip death effector domain derived peptides for inducing autophagy | |
| WO2016007919A3 (en) | Antibody fragments for detecting cancer and methods of use | |
| MX2013003168A (es) | Anticuerpo contra ephrin b2 y su uso. | |
| MX380750B (es) | Composición farmacéutica para tratar y/o prevenir el cáncer. | |
| GB201019467D0 (en) | Therapeutic agent | |
| PH12014502198A1 (en) | Osteoprotegerin derived composition and use thereof | |
| UA108911C2 (xx) | Протираковий злитий протеїн | |
| WO2013052168A3 (en) | Detection aib1-delta 4 protein | |
| TH159052A (th) | ฟิวชั่นโปรตีนต้านมะเร็ง (Anticancer fusion protein) |